Ultragenyx Pharmaceutical Inc. gained FDA orphan status for triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome, also known as De Vivo disease. The Novato, Calif.-based company is conducting a phase II study of triheptanoin, which is a synthetic triglyceride.